A Study of LY2409021 in Patients With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 263 participants.

Also called NCT01241448

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 263 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01241448
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Germany, Italy, Puerto Rico, Romania, Slovakia, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01241448. Randomized; double masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2012-02 (actual). Results posted on 2018-04-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of LY2409021 in Patients With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
LY2409021
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01241448
Content hash
44d20336f3eb45ac187c684e55c3b36c72a12e23520d2a1f6e099470506f9218